Conceptos Categóricos

Crónicas de autores

Sara Cristina Monteiro Gonçalves De Oliveira *

Autora invitada por SIIC

O ESTADO DA ARTE

INTERACÇÕES MEDICAMENTOSAS ENTRE A METADONA E OS ANTI-RETROVIRAIS

Têm sido documentadas inúmeras interacções medicamentosas entre a metadona e os ARV. Contudo, a eficácia dos ARV foi comprovada em doentes infectados com VIH, pelo que, ponderadas as possíveis interacções medicamentosas e a necessidade de ajuste da dose dos fármacos, o início do tratamento não deve ser adiado.

*Sara Cristina Monteiro Gonçalves De Oliveira
describe para SIIC los aspectos relevantes de su trabajo
INTERACÇÕES MEDICAMENTOSAS ENTRE A METADONA E OS ANTI-RETROVIRAIS
Toxicodependências,
16(3):59-66, 2010

Esta revista, clasificada por SIIC Data Bases, integra el acervo bibliográfico
de la Biblioteca Biomédica (BB) SIIC.

Institución principal de la investigación
*Centro Hospitalar de Vila Nova de Gaia/espinho, Vila Nova De Gaia, Portugal
Imprimir nota
Referencias bibliográficas
Bruce, R.D., Altice, F.L., Gourevitch, M.N., Friedland, G.H. (2006). “Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: Implications and management for clinical practice”. J Acquir Immune Defic Syndr, 41, 563-572. Faragon, J.J., Piliero, P.J. (2003). “Drug interactions associated with HAART: Focus on treatments for addiction and recreational drugs”. AIDS Read, 13(9). Ferrari, A., Coccia C., Bertolini, A., Stermieri, E. (2004). “Methadone-metabolism, pharmacokinetics and interactions.” Pharmacological Research, 50, 551-559. Friedland, G., Andrews, L., Schreibman, T., et al. (2005). “Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction”. AIDS, 19(15), 1635-1641. Hendrix, C.W., Wakeford, J., Wire, M.B., et al. (2004). “Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects”. Pharmacotherapy. 24(9). Kharasch, E.D., Bedynek, P.S., Park, S., Whittington, D., Walker, A., Hoffer, C. (2008). “Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance”. Clinical Pharmacology & Therapeutics, 84(4), 497-505. Kharasch, E.D., Bedynek, P.S., Walker, A., Whittington, D., Hoffer, C. (2008). “Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. ritonavir effects on CYP3A and P-glycoprotein activities”. Clinical Pharmacology & Therapeutics, 84(4), 506-512. Kharasch, E.D., Hoffer, C., Whittington, D., Sheffels, P. (2004). “Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone”. Clinical Pharmacology & Therapeutics, 76(3), 250-269. Kharasch, E.D., Mitchell, D., Coles, R., Blanco R. (2008). “Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir”. Antimicrobial Agents and Chemotherapy, 52(5), 1663-1669. Kharasch, E.D., Walker, A., Whittington, D., Hoffer, C., Bedynek, P.S. (2009). “Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity”. Drug and alcohol Dependence, 101, 158-168. Lert, F., Kazatchkine, M.D. (2007). “Antiretroviral HIV treatment and care for injecting drug users: An evidence-based overview”. International Journal of Drug Policy, 18, 255-261. Loughlin, A.M., Schwartz, R., Strathdee, S.A. (2004). “Prevalence and correlates of HCV infection among methadone maintenance attendees: implications for HCV treatment.” International Journal of Drug Policy, 15, 93-101. McCance-Katz, E.F., Rainey, P.M., Jatlow, P., Friedland, G. (1998). “Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262)”. J Acquir Immune Defic Syndr, 18, 435-443. Rainey, P.M., Friedland, G., McCance-Katz, E.F., et al (2000). “Interaction of methadone with didanosine and stavudine”. J Acquir Immune Defic Syndr, 24, 241–248. Smith, P.F., Kearney, B.P., Liaw, S., et al (2004). “Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R-, and S-methadone”. Pharmacotherapy, 24(8). Stine, S.M., Kosten, T.R. (1997). “Methadone dose in the treatment of opiate dependence”. Medscape Psychiatry & Mental Health eJournal, 2(6). Vocci, F.J., Acri,J., Elkashef, A. (2005). “Medication development for addictive disorders: The state of the science”. Am J Psychiatry, 162, 1432-1440. Weber, R., Huber, M., Rickenbach, et al (2009) “Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: The Swiss HIV Cohort Study”. HIV Medicine, 10(7), 407-416. Wong, K., Lee, S., Lim, W. Low, H. (2003). “Adherence to methadone is associated with a lower level of HIV-related risk behaviors in drug users”. Journal of Substance Abuse Treatment, 24, 233-239.


ua40317